Genexine
Business Services · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Bio Innovation Park 172 Magokjungang-ro,...Phone Number
(646) 647-1242Website
www.genexine.comRevenue
<$5 MillionStock Symbol
095700Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Genexine
Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technology platforms are Therapeutic DNA vaccine technology and hyFc® fusion technology. The Company has multiple products clinical development including several undergoing Phase 3 registration trials. The Company's proprietary pipeline includes GX-188 for cervical cancer, GX-I7 (efineptakin alfa) for multiple cancers, GX-H9 (eftansomatropin alfa) for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide.Explore more
Genexine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genexine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Genexine had a recent Job posting/layoffs
Check if Genexine has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Genexine has new funding data
Congratulate Masked Content for being promoted to Masked Content at Genexine
Product Launch: Get notified when Genexine launches new products
Check out if Genexine is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Genexine, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Genexine recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Genexine
Find more new buyers
Company Profile Activity
Activity Insights
Genexine is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Genexine is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Genexine.
Genexine Tech Stack
A closer look at the technologies used by Genexine
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Left Company
Executive Move
New Hire
Executive Move
New Hire
Executive Move
Genexine News & Media
Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline
SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics (hereinafter referred to as 'EPD Bio'), a company developing an innovative targeted protein degradation (TPD) bioPROTAC platform technology, to strengthen its research workforce with expertise in PROTAC technologProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive Officer
(RTTNews) - ProMIS Neurosciences Inc. (PMN), a biotechnology company, said on Wednesday that it has appointed its Board member Neil Warma as inter...Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of itsGenexine’s long-acting growth hormone meets Phase 3 primary endpoint
SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ:095700, CEO Neil Warma), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced positive topline results from the multi-center, randomized, open-label, active-controlled pivotal phase 3 study (CTJ101PGHD301) being conducted in China to evaluate the efficacy and safety of eftansomatropin alfa (Genexine’s proprie
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Genexine
Sign Up For FreeTo access detailed company insights
Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technology platforms are Therapeutic DNA vaccine technology and hyFc® fusion technology. The Company has multiple products clinical development includ... Read More
